Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Beam Therapeutics

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities2.50%
Size of stake in company2.90%
Market capitalizationUSD 2.5 bn

Sector

Gene editing

Main candidate

BEAM-101

Main indications

Sickle cell disease and beta-thalassemia

About the company

Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines. The company was founded in 2017 and is headquartered in Massachusetts in the US. Beam is working on a new approach to genome engineering termed base editing. Base editors have two principal components that are fused together to form a single protein: (i) a CRISPR protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but modified such that they do not cause a double-stranded break, and (ii) a base editing enzyme, such as deaminase, which carries out the desired chemical modification of the target DNA base. This combination enables the precise targeting and editing of a single base pair of DNA. Beam is building a portfolio of product candidates in disease areas such as hematology, oncology, liver diseases and CNS diseases. Most advanced assets are currently in Phase I/II clinical development for Sickle Cell Disease (BEAM-101) and Alpha-1-Antitrypsin Deficiency (BEAM-302).

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.